Reports From the Field: Eye drops lower intraocular pressure
Reports From the Field
Eye drops lower intraocular pressure
The Food and Drug Administration recently approved Rescula, a new synthetic docosanoid compound for the treatment of open-angle glaucoma or ocular hypertension.
Rescula, manufactured by CIBA Vision, the Atlanta-based eye care unit of Novartis, lowers intraocular pressure when used as either a monotherapy or in combination with other drugs. In clinical studies, Rescula maintained a constant level of intraocular pressure throughout the day and showed no loss of efficacy over 12 months.
Patients use Rescula, in the form of eye drops, twice a day. It penetrates the cornea and achieves maximum effect in as soon as 24 hours. It is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure-lowering medications or who fail to achieve target intraocular pressure after multiple measurements over time while taking another intraocular pressure-lowering medication.
More information is available on-line at www.cibavision.com.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.